Rockland Trust Co. Boosts Stake in Pfizer Inc. (NYSE:PFE)

Rockland Trust Co. lifted its stake in Pfizer Inc. (NYSE:PFEFree Report) by 3.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 404,330 shares of the biopharmaceutical company’s stock after purchasing an additional 12,931 shares during the period. Rockland Trust Co.’s holdings in Pfizer were worth $11,220,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. V Square Quantitative Management LLC boosted its holdings in Pfizer by 1,394.1% in the 3rd quarter. V Square Quantitative Management LLC now owns 5,827 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 5,437 shares during the period. Retirement Planning Co of New England Inc. boosted its holdings in Pfizer by 42.2% in the 3rd quarter. Retirement Planning Co of New England Inc. now owns 33,485 shares of the biopharmaceutical company’s stock worth $1,111,000 after buying an additional 9,942 shares during the period. Stifel Financial Corp boosted its holdings in Pfizer by 3.5% in the 3rd quarter. Stifel Financial Corp now owns 13,735,634 shares of the biopharmaceutical company’s stock worth $455,611,000 after buying an additional 465,039 shares during the period. Syntax Advisors LLC boosted its holdings in Pfizer by 14.5% in the 3rd quarter. Syntax Advisors LLC now owns 6,764 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 858 shares during the period. Finally, AlphaCore Capital LLC boosted its holdings in Pfizer by 4.1% in the 3rd quarter. AlphaCore Capital LLC now owns 62,563 shares of the biopharmaceutical company’s stock worth $2,075,000 after buying an additional 2,457 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of NYSE:PFE remained flat at $27.74 during trading on Friday. 52,561,555 shares of the company were exchanged, compared to its average volume of 30,487,030. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $38.99. The company’s 50 day moving average price is $27.67 and its 200 day moving average price is $27.72. The stock has a market cap of $157.19 billion, a PE ratio of -462.34, a PEG ratio of 1.09 and a beta of 0.70.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same period in the prior year, the company posted $1.23 EPS. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. Research analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.06%. The ex-dividend date was Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

Analysts Set New Price Targets

Several research analysts recently weighed in on PFE shares. Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Morgan Stanley increased their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, June 17th. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $35.86.

Get Our Latest Stock Report on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.